BrainScope debuts concussion-rating algorithm on its hand-held device
BrainScope launched a new, FDA-cleared algorithm for its point-of-care, brain-scanning headset that checks for traumatic injuries, hidden bleeds and concussions.

From the Biotech Insider archive. This article dates from Mar 29, 2021 and is preserved as first published.
BrainScope launched a new, FDA-cleared algorithm for its point-of-care, brain-scanning headset that checks for traumatic injuries, hidden bleeds and concussions.
The artificial intelligence-powered Concussion Index takes EEG readings to help establish a baseline for a patient, and assists in diagnosing and monitoring the progression of the condition.
By delivering a score from 0 to 100 in less than 20 minutes—with lower ratings indicating a more severe injury, and 70 being the threshold where a concussion is more or less likely—the index can be used to assess patients at different points in time.
For example, the disposable headset can take a reading directly after a concussion at a sporting event and compare it to changes during the player’s recovery, before making a decision to return to the activity.
“The device operates on a battery charge, making it an ideal choice for assessments on the playing fields or battlefields,” without requiring a blood draw or lab equipment, BrainScope CEO Susan Hertzberg said.
The Concussion Index joins other FDA-cleared algorithms on the BrainScope device, to help triage suspected mild traumatic brain injuries and avoid unnecessary CT scans.
In a validation study, the index was shown to be accurate in identifying the likelihood of a concussion within three days of the head injury, with the device indicated for use in patients between the ages of 13 and 25.


